Table 1.
Relationship Between the Presence or Absence of Frequent Cough at Baseline and Other Baseline Characteristics
| Variable | Frequent Cough |
No Frequent Cough |
P Value | ||
|---|---|---|---|---|---|
| No. | Mean ± SD or Proportion | No. | Mean ± SD or Proportion | ||
| Age, y | 87 | 52.9 ± 9.23 | 54 | 51.0 ± 10.49 | .259 |
| Height, cm | 87 | 166.8 ± 10.0 | 54 | 164.8 ± 9.0 | .219 |
| Weight, kg | 87 | 77.1 ± 17.1 | 54 | 72.7 ± 17.1 | .139 |
| Raynaud syndromea, y | 87 | 4.5 ± 6.7 | 54 | 4.0 ± 4.8 | .638 |
| Non-Raynaud syndromea, y | 87 | 2.5 ± 1.7 | 54 | 2.7 ± 1.9 | .589 |
| Diffuse cutaneous disease, No. (%) | 87 | 49 (56) | 54 | 33 (61) | .579 |
| FVC, percent predicted | 87 | 65.6 ± 8.8 | 54 | 67.8 ± 9.4 | .163 |
| Dlcob, percent predicted | 87 | 51.1 ± 12.0 | 54 | 58.4 ± 12.3 | .001 |
| mRSS skin score | 87 | 13.6 ± 9.6 | 54 | 16.2 ± 11.7 | .170 |
| QLF-LM | 83 | 25.2 ± 19.5 | 53 | 19.0 ± 19.6 | .073 |
| QILD-LM | 83 | 54.1 ± 18.6 | 53 | 46.6 ± 22.3 | .046 |
| QLF-WL | 83 | 9.64 ± 6.7 | 53 | 7.0 ± 7.0 | .032 |
| QILD-WL | 83 | 31.7 ± 13.2 | 53 | 26.1 ± 14.6 | .025 |
| BDI | 80 | 6.9 ± 2.0 | 53 | 7.7 ± 2.4 | .063 |
| PCS, SF-36 | 87 | 35.0 ± 9.8 | 54 | 37.2 ± 9.9 | .211 |
| MCS, SF-36 | 87 | 48.8 ± 8.6 | 54 | 50.7 ± 9.6 | .233 |
| HAQ-DI | 87 | 0.66 ± 0.57 | 54 | 0.80 ± 0.81 | .273 |
| GERD score | 87 | 0.69 ± 0.59 | 54 | 0.38 ± 0.38 | .000 |
| GERD present | 87 | 67 (77) | 54 | 32 (59) | .025 |
| Breathing VAS | 87 | 5.5 ± 4.2 | 54 | 3.3 ± 3.6 | .001 |
| PPI use, No. (%) | 87 | 73 (84) | 54 | 39 (72) | .095 |
| ACE use, No. (%) | 87 | 12 (14) | 54 | 8 (15) | .866 |
| Th-To, No. (%) | 76 | 6 (8) | 50 | 20 (4) | .476 |
| Ro52, No. (%) | 76 | 16 (21) | 50 | 6 (12) | .235 |
| ANA, No. (%) | 81 | 4 (5) | 52 | 3 (6) | .999 |
| Centromere, No. (%) | 81 | 3 (4) | 52 | 0 (0) | .280 |
| Topoisomerase, No. (%) | 81 | 38 (47) | 52 | 23 (44) | .762 |
| RNA polymerase, No. (%) | 81 | 9 (11) | 52 | 8 (15) | .471 |
Scoring scales: BDI range = 0-12, with lower scores indicating worse dyspnea. Breathing VAS range = 1-100, with higher numbers indicating increasing difficulty breathing. PCS, SF-36 and MCS, SF-36 range = 0-100, with lower scores indicating worse health status. mRSS range = 0-51, with higher scores indicating more severe thickening. HAQ-DI range = 1-3, with higher numbers indicating greater disability.
ACE = angiotensin-converting enzyme inhibitor; ANA = antinuclear antibody; BDI = baseline dyspnea index; Dlco = diffusing capacity of the lung for carbon monoxide; GERD = gastroesophageal reflux disease; HAQ-DI = Health Assessment Questionnaire Disability Index; HRCT = high-resolution CT; LM = lobe of maximal involvement; MCS = mental component scale; mRSS = modified Rodnan skin score; PCS = physical component scale; PPI = proton pump inhibitor; QILD = quantitative interstitial lung disease; QLF = quantitative lung fibrosis; Ro52 = antibodies to Ro52 kilodalton; SF-36 = 36-Item Short Form Survey; SSc = systemic sclerosis; Th/To = antibodies to Th/To ribonucleoprotein; VAS = visual analog scale; WL = whole lung.
Years since first Raynaud or non-Raynaud symptom of SSc.
Adjusted for hemoglobin.